Matching-adjusted indirect comparison: entrectinib versus crizotinib in ROS1 fusion-positive non-small cell lung cancer

To perform indirect treatment comparisons of entrectinib versus alternative fusion-positive non-small cell lung cancer treatments. Relevant studies with crizotinib and chemotherapy as comparators of interest identified by systematic literature review were selected for matching-adjusted indirect comp...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of comparative effectiveness research 2020-08, Vol.9 (12), p.861-876
Hauptverfasser:	Chu, Paula, Antoniou, Miranta, Bhutani, Mohit K, Aziez, Amine, Daigl, Monica
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - therapeutic use Benzamides - therapeutic use Blood-brain barrier Cancer therapies Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - metabolism Carcinoma, Non-Small-Cell Lung - pathology Cell growth Chemotherapy Crizotinib - therapeutic use FDA approval Humans Indazoles - therapeutic use Inhibitor drugs Kinases Literature reviews Lung - drug effects Lung - metabolism Lung - pathology Lung cancer Lung Neoplasms - drug therapy Metastasis Mutation Patients Protein-Tyrosine Kinases - antagonists & inhibitors Protein-Tyrosine Kinases - metabolism Proto-Oncogene Proteins - antagonists & inhibitors Proto-Oncogene Proteins - metabolism Signal transduction Systematic review Targeted cancer therapy Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!